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ARTICLE
Variant-specific inflation factors for assessing
population stratification at the phenotypic variance
level
Tamar Sofer 1,2,3✉, Xiuwen Zheng 4, Cecelia A. Laurie 4, Stephanie M. Gogarten 4,
Jennifer A. Brody 5, Matthew P. Conomos 4, Joshua C. Bis4, Timothy A. Thornton4, Adam Szpiro4,
Jeffrey R. O’Connell6, Ethan M. Lange7, Yan Gao8, L. Adrienne Cupples 9,10, Bruce M. Psaty5, NHLBI Trans-
Omics for Precision Medicine (TOPMed) Consortium* & Kenneth M. Rice 4
In modern Whole Genome Sequencing (WGS) epidemiological studies, participant-level data
from multiple studies are often pooled and results are obtained from a single analysis. We
consider the impact of differential phenotype variances by study, which we term ‘variance
stratification’. Unaccounted for, variance stratification can lead to both decreased statistical
power, and increased false positives rates, depending on how allele frequencies, sample sizes,
and phenotypic variances vary across the studies that are pooled. We develop a procedure to
compute variant-specific inflation factors, and show how it can be used for diagnosis
of genetic association analyses on pooled individual level data from multiple studies.
We describe a WGS-appropriate analysis approach, implemented in freely-available
software, which allows study-specific variances and thereby improves performance in
practice. We illustrate the variance stratification problem, its solutions, and the proposed
diagnostic procedure, in simulations and in data from the Trans-Omics for Precision Medicine
Whole Genome Sequencing Program (TOPMed), used in association tests for hemoglobin
concentrations and BMI.
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Large-scale association analyses using whole genomesequence (WGS) data on thousands of participants are nowunderway, through programs such as the NHLBI’s Trans-
Omics for precision Medicine (TOPMed) program and NHGRI’s
Genome Sequencing Program. Unlike earlier Genome-Wide
Association Studies (GWASs), where data were combined using
meta-analyses of summary statistics, in WGS analyses
participant-level data from multiple studies are often pooled, and
results are obtained from a single analysis. Pooled analysis of
WGS is useful due to its computational tractability and its ability
to control for genetic relatedness across the pooled datasets.
However, it is sensitive to a form of population stratification that
is not well known. Population stratification in genetic association
analysis1,2 typically refers to situations where the mean pheno-
type value and allele frequency both differ across population
subgroups. Unless appropriately accounted for in the analysis,
e.g., by using regression-based adjustments for ancestry such as
principal components or genetic relatedness matrices in linear
mixed models, or their combination, it can lead to false–positive
associations3–5. Population stratification more generally can refer
to differences in phenotype distribution and allele frequency
across population subgroups6, and hence can also manifest as
differences in phenotype variances by subgroup, combined with
differences in allele frequencies. In practice, this phenomenon is
common in pooled analysis of multi-study data, as small differ-
ences in allele frequencies are prevalent, and different studies
being pooled often have different measurement protocols,
environmental exposures and inclusion criteria, all of which can
lead to different phenotype variances among studies.
Previous studies considered the effect of combining together
groups with different phenotypic variances. Haldar and Ghosh6
studied the effect of population stratification due to mean dif-
ferences, variance differences, and more generally, phenotypic
heterogeneity, across subpopulations, on false positive detections
when testing variant associations with a quantitative trait. Con-
omos et al.7 showed that when testing variant associations in a
pooled sample of Hispanics/Latinos from different Hispanic
background groups, statistical properties of tests are improved
when the model allows for different residual variances in the
different background groups. Musharoff et al.8, in a preprint,
studied population variance structure using statistical models of
both population means and variances, and developed statistical
tests for the association of genetic variants with phenotypic
variability.
In this manuscript, we develop variant-specific inflation factors
λvs, which quantify the degree of inflation/deflation in association
testing of a single genetic variant due to population stratification
at the variance level. We develop an algorithm to compute
approximate variant-specific inflation factors based on allele
frequencies and variances in groups pooled together for analysis,
demonstrate their usage for assessing model fit, and demonstrate
the implications of the population stratification at the variance
level in simulations and in analyses of WGS data from TOPMed.
To account for population stratification at the variance level we
use the computationally efficient and scalable approach proposed
in Conomos et al.7 and implemented in GENESIS9, and show in
simulations that it indeed addresses the variance stratification
problem in scenarios based on Musharoff et al.8.
Results
Simulation studies. Our simulations consisted of 576 simulation
settings according to various combinations of parameters. We
compared a few ways to estimate variance parameters to be used
in computing λvs: empirical variances based on homogeneous and
stratified variance models, and model-based variances from the
heterogeneous variance model. The estimated λvs were essentially
the same regardless of the method. Figure 1 compares the esti-
mated λvs to the observed λgc in each of the simulation settings
and in each of the two modeling approaches (homogeneous
versus stratified variance). Settings are divided according to pat-
terns determining whether variance stratification will be expected,
including same or different MAFs between the two studies, the
same or different error variances, and whether the PC affects the
genetic variance or not. The top three rows in Fig. 1 demonstrate
settings in which both the MAF and the total variances differ
between the two combined studies, including settings in which
both the error and genetic variance components are the same, but
the PC affects the genetic variance, resulting in different total
variance between the studies because the mean of the PC differs
between them. In these settings the variance stratification is
observed when using the homogeneous variance model, in that
the observed inflation can be substantially higher or lower than 1,
with exact values depending on the specific parameters used in
each simulation. Indeed, the computed λvs and the observed λgc
are highly correlated. In contrast, the stratified variance model
was robust to variance stratification across all settings, with
observed inflation around 1 in all simulations. The bottom two
rows of Fig. 1 demonstrate settings in which either the MAF or
the variances are the same in the two combined studies. In these
settings, the expected inflation computed by λvs is always 1 (no
inflation). As expected, the observed inflation is the same in the
homogeneous and stratified variance models. The spread seen in
the values of the observed inflation, with some values higher and
some lower than the desired 1, are consistent with that expected
based on the number of replication of simulations in each setting
(10,000); see Supplementary Information for more details.
Genetic association analysis of BMI and hemoglobin con-
centration in TOPMed. We demonstrate the variance stratifi-
cation problem in analyzes of hemoglobin concentrations (HGB,
N= 7596; three analysis groups) and body mass index (BMI, N=
9807; eight analysis groups) in the TOPMed freeze 4 dataset. In
both analyses we computed approximate variant-specific inflation
factors λvs. We investigated the inflation/deflation problems
resulting from variance stratification, and verified that the pat-
terns of inflation and deflation in the homogeneous variance
analysis agree, across the different variants, with those obtained
from the formula and the provided code. Figures 2 and 3 provide
quantile-quantile (QQ)-plots for variants from three categories of
variants, where theory predicts inflation ðλvs ≥ 1:01Þ, deflation
ðλvs ≤ 0:99Þ and variants with λvs “Approx. no inflation”
(0:99<λvs<1:01), and across all variants, for HGB and BMI ana-
lyses respectively. The plots overlay the results from the four
analyses methods together. While the homogeneous variance
model clearly produces inflated and deflated QQ-plots in line
with the theoretical expectation, when looking at all tested var-
iants together, this inflation and deflation (i.e., Type I and Type II
errors) mask each other, alarmingly. Despite appearances, these
problems do not “cancel out”; one creates more Type I errors, one
creates more Type II errors, yet the plot of all results may lead
investigators to conclude that the analysis is well-calibrated. In
contrast, the stratified residual variance model provides good
control of Type I errors, as seen in the QQ-plots, with the
exception of the bottom left panel in Fig. 3, which provides QQ-
plots for the set of variants that are expected to have deflated test
statistics under the pooled variance model when studying BMI:
here the stratified residual variance model was also somewhat
deflated. Figure 4 provides the genomic control inflation factors
λgc computed over each of the variant sets provided in the QQ-
plots and for each of the traits. The completely stratified and
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MetaCor models performed better in terms of overall QQ-plots
and computed λgc values in the two analyses, in that λgc values
were always closer to 1. MetaCor performed slightly better than
the completely stratified model under independence, likely
because it accounts for a low degree of relatedness between the
strata.
Table 1 describes the inflation/deflation patterns of variants
according to their MAF. One can see that the inflation/deflation
Stratified variance Homogeneous variance
















Resid var 1 < resid var 2, MAF 1 < MAF 2
Resid var 1 < resid var 2, MAF 1 > MAF 2
Resid var 1 > resid var 2, MAF 1 < MAF 2
Resid var 1 > resid var 2, MAF 1 > MAF 2
Different residual variances, different MAF, PC affects genetic variance
Stratified variance Homogeneous variance














Resid var 1 < resid var 2, MAF 1 < MAF 2
Resid var 1 < resid var 2, MAF 1 > MAF 2
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Different residual variances, different MAF, no PC effect on genetic variance
Stratified variance Homogeneous variance

















Resid var 1 = resid var 2, MAF 1 < MAF 2
Resid var 1 = resid var 2, MAF 1 > MAF 2
Equal residual variances, different MAF, PC affects genetic variance
Stratified variance Homogeneous variance















Resid var 1 = resid var 2, MAF 1 < MAF 2
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Equal residual variances, different MAF, no PC affect on genetic variance
Stratified variance Homogeneous variance
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Fig. 1 Estimated variant-specific inflation factors versus observed inflation in simulations. The figure compares estimated variant-specific inflation
factors λvs estimated in each of many simulation settings, and corresponding observed inflation λgc averaged across 10,000 repetitions of each simulation
settings. Observed inflation values are provided based on a homogeneous variance model, in which a single variance parameter is estimated using the
aggregated data; and based on a stratified variance model, that fits a different variance parameter to each of the two simulated studies. Each simulation set
corresponds to a single point on this figure, and the simulations are grouped (denoted by different colors and symbols) by the characteristics stated in the
legend. Within each group of simulation settings, the simulation parameters differ by specific parameter values, including MAFs, variance components, and
sample sizes, while still satisfying the broad conditions of the grouped simulation settings. The dashed horizontal lines correspond to the 2.5% and 97%
quantiles of the distribution of λgc based on 10,000 variants under the null of no inflation/deflation, obtained from simulations.
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problem is ubiquitous for rare variants, but less so for common
variants. In fact, for variants with frequency <0.05, only ~4% of
variants have λvs falling in the “approximately no inflation”
category. This is because the ratio between allele frequencies has a
strong effect on inflation/deflation, and ratios can become quite
high when variants are rare. In the Supplementary Information,
Figure S2 shows the distribution of inflation, deflation, and
“approximately no inflation” categories across variants in the two
analyses, and demonstrates how similar the deflation/inflation
categories are between them. Most variants stay in the same
category between analyses, but some rare variants (in the figure
defined as MAF < 0.05) can be inflated in one analysis and
deflated in the other. These differences are because λvs coefficients
are affected by sample sizes, variances, and allele frequencies,
which all differ to some extent between analyses due to different
samples and trait characteristics.
Discussion
A standard tool for analysis of quantitative traits is linear or linear
mixed model regression. In its widely-used default version, linear
regression is fitted under the assumption that the phenotype’s
residual variance is the same for all individuals in the analyzed
sample. The extent of the consequences if the variances are not
equal sized can be computed exactly given simplifying assump-
tions. Broadly, using default approaches, if a specific subgroup
has a larger phenotypic variance than that of other subgroups in
the pooled analysis, the estimated precision of the association
signal will understate the contribution from such a subgroup. The
result is deflation (loss of power) for variants where allele fre-
quency is greater in this subgroup compared to other subgroups,
or inflation (too many false positives) for variants with lower
allele frequency in this subgroup compared to others.
While default linear regression methods assume the same
variance for all subgroups, which leads to mis-calibrated tests if
the assumption does not hold, standard computational tools can
be adapted to allow for a stratified variance model, yielding better
calibrated tests. Specifically, by fitting different residual variances
for each study, or more generally, appropriately defined “analysis
group” (e.g., all African Americans of a specific study) the pro-
blem can be alleviated. This can be viewed as fitting a different
variance component for noise within each study, or as a weighted
Fig. 2 QQ-plots comparing observed and expected p values (−log10 transformed) from the analysis of hemoglobin concentrations. The analyses used
four approaches: “homogeneous variance” model, that assumes that all groups in the analysis have the same variances; “stratified variance” model, that
allows for different residual variances across analysis groups; a “completely stratified indep” model in which analysis groups were analyzed separately,
allowing for both heterogeneous residual and genetic variances across groups, and then combined together in meta-analysis under independence
assumption, and “MetaCor”, a procedure that accounts for relatedness across strata in the meta-analysis. The QQ-plots are provided across sets of
variants classified by their inflation/deflation patterns according to the algorithm for variant-specific approximate inflation factors. We categorized variants
as “Approx. no inflation” when they had estimated λvs between 0.99 and 1.01, “Deflated” when estimated λvs lower than 0.99, and “Inflated” when they had
estimated λvs higher than 1.01.
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least squares approach, in which the group-dependent weights are
estimated. This approach is implemented in some standard
genetic analysis software packages (e.g., GENESIS9). Our math-
ematical derivation and code can be used to assess the degree of
miscalibration of association tests. The code uses an additive
model, using a Binomial distribution for allele counts, which is
commonly used in GWAS. Inflation/deflation trends should be
similar between additive and dominant models, though specific
values estimated using each of the two models would not be
identical.
In linear regression, the stratified residual variance model
allows every analysis group to have its own residual variance
parameter. In the mixed model setting, where the variance is
decomposed into genetic and residual variances, this model keeps
the genetic variance component the same but allows for the
residual variance to differ across groups. Analysis groups can be
defined as study, race/ethnicity, combinations of these, or any
other sample characteristics that affect trait variance and may also
correlate with allele frequencies. Our mathematical derivation
and code for computing λvs are under simplifying assumptions of
no covariate effects and independent observations. Therefore,
these make no distinction between genetic and residual variance
components. While in the linear regression setting (independent
observations) the variance stratification model clearly suffices to
account for variance heterogeneity, in the mixed model setting, a
residual variance stratification model may not be optimal, because
it may not fully account for stratification in the genetic variance,
which could be the result of study design. For example, in Fig. 5,
the estimated genetic variance component of the Cleveland
Family Study is much higher than those of other studies, and of
the residual variance component of the same study, perhaps
because study participants were selected from families with
obstructive sleep apnea, which is highly associated with obesity.
Heterogeneity in genetic variance is addressed in the “completely
stratified model”, but such a model requires that individuals are
independent between different groups (strata). We also used
MetaCor, a method that allows for complete stratification of
analysis groups, while keeping genetically related individuals
across these groups15. MetaCor was shown to have good statis-
tical properties and performed well in the BMI and HGB analysis.
However, it is currently computationally costlier than a pooled
analysis because individual level data are used both at the
Fig. 3 QQ-plots comparing observed and expected p values (−log10 transformed) from the analysis of BMI. The analyses used four approaches:
“homogeneous variance” model, which assumes that all groups in the analysis have the same variances; “stratified variance” model, which allows for
different residual variances across analysis groups; a “completely stratified indep” model in which analysis groups were analyzed separately, allowing for
both heterogeneous residual and genetic variances across groups, and then combined together in meta-analysis under independence assumption, and
“MetaCor”, a procedure that accounts for relatedness across strata in the meta-analysis. The QQ-plots are provided across sets of variants classified by
their inflation/deflation patterns according to the algorithm for variant-specific approximate inflation factors. We categorized variants as “Approx. no
inflation” when they had estimated λvs between 0.99 and 1.01, “Deflated” when estimated λvs lower than 0.99, and “Inflated” when they had estimated λvs
higher than 1.01.
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individual analysis group computations, and when computing
covariances between effect size estimates of all analysis groups.
Computational efficiency is critical when testing the large number
of variants observed in WGS studies. In addition, the MetaCor
approach is not yet extended to tests of sets of rare variants
(rather than single rare variants tests studied in the current
manuscript). While more difficult to assess, variance stratification
likely affects tests of rare variant sets as well, and methods that
use a Score test based on a null model that is fit once, such as the
stratified variance approach implemented in GENESIS, straight-
forwardly extend to such settings. As sample sizes of TOPMed
grow, pooling together more diverse studies and populations,
variance stratification problems may be more severe. Models
allowing for pooled analysis with both group-specific residual and
genetic variances or robust variance estimates may be needed for
better control of Type I errors and increased efficiency. Until such
methods are developed, we recommend to first use the stratified
variance approach, because it is computationally efficient, it can
account for relatedness across the entire sample, and the same
null model can be used to test variant sets. As a second step, we
recommend computing approximate λvs, and assessing whether
observed inflation/deflation remains for test statistics within
groups of variants predicted to be inflated/deflated based on λvs
values. If inflation/deflation are observed despite residual variance
stratification, the analyst would ideally move forward with a
meta-analytic approach such as MetaCor (does not discard data
but computationally more demanding), or standard meta-analysis
after removing individuals to generate genetically independent
strata.
Methods
The linear model. For a total sample size of n, we assume that the data follow a
linear model denoted as
yi ¼ β0 þ giβþ ϵi; 1≤ i≤ n; ð1Þ
where yi is the trait or phenotype value of person i, gi is their count of coded alleles
(i.e., genotype), β0 denotes the mean outcome in those with no copies of the coded
allele, β denotes the effect on the mean trait of each additional copy of the coded
HGB
BMI














Homogeneous_variance Stratified_variance MetaCor Completely_stratified_indep
Fig. 4 Estimated genomic control inflation factors (λgc) across compared analyses. The figure provides estimated λgc from the various analyzes of BMI
and hemoglobin concentrations, computed across sets of variants classified by their inflation/deflation patterns according to the algorithm for approximate
variant-specific inflation factors (λvs). We categorized variants as “Approx. no inflation” when they had estimated λvs between 0.99 to 1.01, “Deflated” when
estimated λvs were lower than 0.99, and “Inflated” when they had estimated λvshigher than 1.01. Genomic control inflation factors λgc were computed as the
ratio between the median χ21 test statistic across variants in the set to the theoretical median of the test statistic under the null hypothesis of no
association.






(0, 0.9] (0.9, 0.95] (0.95, 0.99] (0.99, 1.01] (1.01, 1.05] (1.05, 1.1] (1.1, 1.24]
BMI
[0.00102, 0.01] 13151242 14.47% 48.96% 7.25% 4.39% 19.74% 4.93% 0.25%
(0.01, 0.05] 5497411 0.99% 63.77% 6.34% 4.14% 24.23% 0.53% –
(0.05, 0.2] 3393012 – 19.37% 27.68% 23.15% 29.80% <0.01% –
(0.2, 0.5] 3318076 – 0.16% 11.40% 70.64% 17.80% – –
HGB
[0.00134, 0.01] 11140793 – 64.79% 9.05% 3.04% 19.97% 3.15% –
(0.01, 0.05] 6047232 – 64.41% 9.45% 5.29% 20.81% 0.04% –
(0.05, 0.2] 3704075 – 19.59% 29.49% 23.54% 27.38% – –
(0.2, 0.5] 3358855 – 0.20% 12.08% 73.15% 14.58% – –
In each of the analyses (BMI and HGB), for each allele frequency category we provide the number of variants in this category, and from these, the proportion of variants with computed λvs in each of
multiple categories of inflation/deflation values.
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allele, and the ϵi are residual errors, which we for now assume are independent, as a
simplifying assumption.
To provide intuition for the variance stratification problem, we first
demonstrate a mathematical derivation in simplified settings. We assume that the
genotype effect is null (β= 0), and that the errors follow a normal distribution
ϵi  Nð0; σ2i Þ. We further assume that the phenotypes are centered, the genotypes
are centered, and follow a dominant mode of inheritance, i.e., we are using
gi ¼ ð~gi  pÞ, where ~gi is the genotype under a dominant mode (having values 1 or
0), p is the frequency of having any copies of the variant allele, and gi is used in
analysis.
Implication of variance stratification on the Wald test. The Wald test quantifies
the strength of the genetic association by dividing a regression-based estimate of β
by its corresponding estimated standard error. The linear regression estimate of the












Denoting the estimated residual variance of individual i by σ2i (which may differ































where σ2 is the common variance parameter. To illustrate how this approach can
mislead under variance stratification, we consider the situation where two studies
are present, of sizes n1 and n2, respectively, such that n1 þ n2 ¼ n: Further, each
study is internally homogeneous with error variances σ21 and σ
2
2, and it is also useful
to write p1 and p2 for the frequency of the variant of interest (under dominant
mode). Because we assume that the variant was centered in the pooled population,
we have that E½∑
i2Sj
g2i  ¼ niE½g2i  ¼ ni½pið1 piÞ2 þ ð1 piÞð0 piÞ2, or
E½∑
i2Sj
g2i  ¼ nipið1 piÞ: We can re-write Eq. (3) as:
varðβ̂Þ ¼ n1p1ð1 p1Þσ
2
1 þ n2p2ð1 p2Þσ22
½n1p1ð1 p1Þ þ n2p2ð1 p2Þ2
ð5Þ
We see that the actual variance is a linear combination of the variance parameters
σ21; σ
2
2, and the weight assigned to each depends on the minor allele frequency and
sample size in each group. When the minor allele frequencies (MAFs) are equal, p1
= p2, the two forms4 and5 are equal, as there is no association between genotype
and outcome, and no confounding occurs. But when p1 ≠ p2 then the variance of
the estimator upweights the residual variance in the group where the variant is
more common, which does not happen under homogeneity. This result
straightforwardly generalizes for M studies.
In some studies, researchers use mixed models in GWAS to account for genetic
relationships between individuals. Then, it is usually assumed that the variance is
decomposed to an error and genetic variances, so that varðϵÞ ¼ σ2e þ σ2g . When
using unrelated individuals and not accounting for genetic relatedness via a genetic
relationship matrix, the two variance components are not identifiable and it is clear
that accounting for differences in error variances is the same as accounting for
differences in total variance (the sum of the two variance components). Musharoff
et al.8 introduced a model where the variances depends on individual-specific
genetic components. For example, it could depend on a principal component (PC)
of the genetic data, with: varðϵÞ ¼ σ2e þ θ2gσ2g where θg is a PC, with values varying
across individuals. We address this setting in simulations.
Computing approximate variant-specific inflation factors. We can use mathe-
matical derivations under homogeneity and heterogeneity, relaxing the restrictive
assumptions provided earlier, to compute variant-specific inflation factors. These
make use of standard “sandwich” formula for large-sample approximations of the
variance of estimators; for a minimally-technical summary see Result 2.1 in
Wakefield10, or for more detail Sections 5.2–5.3 of Van der Vaart11. We now allow
for additive genetic model, and do not assume that the genotypes are standardized.




















































































































































































Genetic variance component Residual variance component
Fig. 5 Estimated variance components across compared analyses. The figure provides the estimated variance components corresponding to residual and
genetic relatedness in the analyzes of BMI and hemoglobin concentration (HGB). For each analysis group, the estimated variance components were
computed based on the analysis of the group alone, and were extracted from the second null model in the fully-adjusted two-stage rank-normalization
procedure, to match the procedure used for association analysis.
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but allowing for different variances per study, it becomes:












































































Based on these two expressions, we propose an algorithm to compute an
approximate variant-specific inflation factor. For computational purposes, we
further simplify these arguments taking advantage of the fact that there are
repeated rows (e.g., people who have gi= 1 and are from the same study, having the
same residual variance). The algorithm below uses the additional assumption that
phenotypic variance within each study does not vary with genotype—which must
hold under the strong null hypothesis of no association in any subpopulation. It
also uses the simplifying assumption that variants are in Hardy Weinberg
Equilibrium (HWE) within each study population; testing HWE is a standard
preprocessing step for genotype data.
Algorithm for computing variant-specific inflation factors
Suppose that an analyst wished to estimate a vector of regression
parameters ðβg ; β1; ¼ ; βMÞT , where βg is a variant association
measure, and β1; ¼ ; βM are intercepts for M analysis groups.
Denote the genotype of the ith individual in the m analysis group
by gmi. The design matrix for estimating these parameters in
linear regression would be of the form
g1 1n1 0n1 ¼ 0n1












where gm ¼ ðgm1; ¼ ; gmnm Þ
T , 1nm is a vector of length nm with all
entries being equal to 1, and similarly 0nm is a vector of length nm
with all entries being equal to 0. Let V ¼ varðyÞ be the diagonal
matrix with error variances of the outcomes. The estimator of the
variances and covariances of the vector of regression parameters
is varðβ̂Þ ¼ ðWTWÞ1WTVWðWTWÞ1. From the matrix varðβ̂Þ
we are interested in the leading diagonal value, which is the
variance of bβg . Suppose first that one construct the matrix W









2 1n2 ¼ gMT1nM
gT1 1n1 n1 0 ¼ 0












Now, instead of using the genotype themselves, we use the
large sample limit of the expected genotype under HWE to
replace the expression gTm1nm by
nm ´ ð0 ´ p2m þ 1´ 2pmð1 pmÞ þ 2 ´ ð1 pmÞ2Þ, where nmp2m,
2nmpmð1 pmÞ, and nmð1 pmÞ2 are the number of individuals
from analysis group m expected to have 0, 1, and 2 effect alleles
under HWE. Similarly, we can replace gTmgm by its large sample
limit under HWE.
Notice that the quantity 0 ´ p2m þ 1 ´ 2pmð1 pmÞ þ
2 ´ ð1 pmÞ2 is a multiplication of two vectors:
ð0; 1; 2Þ ´ ðp2m; 2pmð1 pmÞ; ð1 pTmÞÞ
T
. Thus, we now define a
matrix X and a matrix p, such that ðWTWÞ ¼ XTPX. In matrix X
the left column having values ð0; 1; 2; ¼ ; 0; 1; 2ÞT (ð0; 1; 2ÞT
repeating for each study), instead of the actual observed geno-
types ðg11; ¼ ; gMnM Þ
T , other columns represent study-specific
intercepts, and the matrix P is a diagonal matrix providing the
HWE probabilities, for each study, further scaled by the pro-
portion of individual that each analysis group contributes to the
study. We use the matrices X, P, and V = var(y) to similarly
replace WTVW by its large sample limit under HWE. Specifically,
define:
● X ¼ ðGDÞ where G is a vector of length 3M of the form
ð0; 1; 2; ¼ ; 0; 1; 2ÞT , and D is a 3M ×M design matrix
modeling study-specific intercepts where the i, j element Dij
is
1 if i ¼ 3m; 3m 1 or 3m 2; j ¼ m
0 otherwise:

● P, a 3M × 3M diagonal matrix, in which each entry gives
the population proportion in each combination of genotype
and study, i.e.,:




















V, is a 3M × 3M diagonal matrix, in which each entry gives the
outcome variance in each combination of genotype and study.
V ¼ diagðσ21; σ21; σ21; ¼ ; σ2M ; σ2M ; σ2MÞ
Define now B ¼ XTPX and A ¼ XTPVX, which give the large
sample limits of ðWTWÞ and WTVW. Under heterogeneity the
variance of the slope estimate bβg is proportional to the leading
diagonal entry B1AB1. Under homogeneity the variance bβg is
proportional to the leading entry of B1 ´ sumðdiagðPVÞÞ, with
the same constant of proportionality. The ratio of these two
leading entries, squared, gives the large-sample value of λgc, the
genomic control inflation factor12 that would be obtained by
comparing the median Wald test statistic to the median of the χ21
reference distribution, if all variants had the same MAF values
across the studies. Because this formula provides different results
for each variant, depending on the allele frequencies, we denote
the ratio between the estimated values under homogeneous var-
iance and the heterogeneous variance models λvs, for “variant
specific”. Note that this function requires estimation of variances
(for constructing matrix P, under HWE assumption) and allele
frequencies (for constructing matrix V), which are readily
obtained.
An R function implementing these matrix calculations is pro-
vided, together with a tutorial that includes a coding example.
These are also provided on GitHub on https://github.com/
tamartsi/Variant_specific_inflation, and the function will be
integrated into the GENESIS R package.
Simulation studies. We performed simulations to study the
appropriateness of the proposed λvs, in terms of how it approx-
imates the standard genomic control coefficient λgc obtained from
a “homogeneous variance” model that estimates a single variance
parameter across data from all studies. We also studied whether a
“stratified variance” model, allowing for different variance para-
meters across two studies, improves upon the homogeneous
variances model. In this vein, we simulated unassociated genetic
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variants and outcomes in a range of settings combining two
studies. We simulated n1; n2 individuals in study 1 and study 2,
n1 þ n2 ¼ n. Let yi be the outcome value of person
i; i ¼ 1; ¼ ; n, and θi a PC value for this person, β1 ¼ 1; β2 ¼ 2
be study-specific intercepts for studies 1 and 2, σ21; σ
2
2study-
specific error variances, σ2g a common genetic variance parameter,
and βθ ¼ 1 models the linear association of the PC with the
outcome. The PC was simulated from a normal distribution with
variance 1, and mean μ1 ¼ 2 in study 1, and mean μ2 in study 2
computed such that the overall PC mean in the two studies







outcome model specified as:
yi ¼ α11study1 þ α21study2 þ θiαθ þ ϵi; ð6Þ
With













In7 the PC does not affect the genetic outcome variance, while
in8 it does. Some of the parameters were the same in all
simulations (as reported above). We varied the following
parameters: n1; n2 2 f1000; 5000g, σ21; σ22; σ2g 2 f1; 2g; and simu-
lated bi-allelic independent genetic variants with MAFs p1; p2 2
f0:01; 0:05; 0:5g in the two studies.
We performed 10,000 simulations for each combination of
parameters and, for each such setting, computed λgc as the ratio
between median observed and expected value of the χ2ð1Þ test
statistic (under the null). We computed λvs in each of the
10,000 simulations based estimated variances and observed allele
frequencies in each of the two simulated studies, and averaged
these estimates across the simulations. We compared three
approaches to estimate variances1: fit a homogeneous variances
model, obtain residuals ϵ̂: For each study, estimate the variance as
the average 1=n ∑
n
i¼1
bϵ2i where n is the number of study individuals
(empirical variance)2; fit a “stratified variance” linear regression
model allowing for different residual variances by study (as
implemented in the R/Bioconductor package GENESIS9);3 use
the same model with stratified variances, but use the variance
estimates obtained by the AI-REML algorithm (model variance).
In the Supplementary Information, we provide a distribution of
λgc values that would be seen under random variability, using
10,000 independent test statistics (as was used in simulations),
and simulating test statistics under the null and computing
inflation factors λgc.
Whole genome sequencing in TOPMed. For the present analysis,
we used Whole Genome Sequencing (WGS) data from freeze 4 of
TOPMed. WGS was performed on DNA samples extracted from
blood. Sequencing was performed by the Broad Institute of MIT and
Harvard (FHS and Amish) and by the Northwest Genome Center
(JHS). PCR-free libraries were constructed using commercially
available kits from KAPA Biosystems (Broad) or Illumina TruSeq
(NWGC). Libraries were pooled for clustering and sequencing, and
later de-multiplexed using barcodes. Cluster amplification and
sequencing were performed according to manufacturer’s protocols
using the Illumina cBot and HiSeq X sequencer, to a read depth of
>30X. Base calling was performed using Illumina’s Real Time
Analysis 2 (RTA2) software. Read alignment, variant detection,
genotype calling and variant filtering were performed by the
TOPMed Informatics Research Center (University of Michigan).
Reads were aligned to the 1000 Genomes hs37d5 decoy reference
sequence. Variant detection and genotype calling were performed
jointly for several TOPMed studies (including the three analyzed
here), using the GotCloud pipeline. Mendelian consistency was used
to train a variant quality classifier using a Support Vector Machine,
used for variant filtering. Additional quality control (pedigree
checks, gender checks, and concordance with prior array data),
performed by the TOPMed Data Coordinating Center, were used to
detect and resolve sample identity issues. Further details (including




TOPMed analyses were performed in agreement with study
participants’ consent, as verified via an approval process by parent
studies PIs in TOPMed and TOPMed publication committee.
Variant-specific inflation and genetic association analysis of
BMI and hemoglobin concentration in TOPMed. To demon-
strate the variance stratification problem, we used datasets of
hemoglobin concentrations (HGB) and body mass index (BMI)
in the TOPMed freeze 4. For each of the traits, we computed a
Genetic Relationship Matrix (GRM13) on all available variants for
the corresponding trait with minor allele frequency at least 0.001,
which was used to control for genetic relatedness in mixed
models. Because some studies had individuals with different
genetic backgrounds (leading to differences in allele frequencies),
we defined “analysis groups” to use for assessment of variance
stratification. An analysis group was as either all individuals from
a single study (e.g., Amish), or further defined by both study and
race/ethnic group (e.g., European and African Americans from
the Cleveland Family Study were separate analysis groups). Thus,
analysis groups capture multiple potential sources of trait var-
iance, including differences in allele frequencies due to genetic
ancestry, differences in environment and social/cultural factors,
and differences in trait measurement by study. For both BMI and
HGB, we performed single-variant association analysis for all
variants with minor allele count of at least 20. Detailed break-
down of the studies and populations used in these analyses are
provided in the Tables 2 and 3. The analysis strategy for both
traits was to use the fully-adjusted two-stage procedure for rank-
normalization of residuals, because it was shown to have better
statistical properties (type 1 error control and power), especially
when testing possibly rare genetic variants14. Thus, we first fit a
mixed linear regression model, with fixed effects for sex, age (also
age2 for BMI), group defined by study and race/ethnicity, and
allowing for genetic relatedness by including a variance compo-
nent proportional to the GRM. Then we took the residuals gen-
erated by this model, rank-normalized them, and then re-fit the
same model but with the rank-normalized residuals as the trait.
For both traits, we compared four analyses: first, a ‘homogeneous
variance’ analysis that estimates a single residual variance para-
meter across all individuals; second, a “stratified residual var-
iance” model that allows a different residual variance parameter
for each analysis group; third, a “completely stratified” approach
which fits models and performs tests in each analysis group
separately, and then combines the results via inverse-variance
fixed-effects meta-analysis; and forth, a “MetaCor” analysis15 that
perform stratified analyses followed by fixed-effects meta-analysis
while accounting for potential correlations due to genetic rela-
tionships between individuals in different analysis groups. The
‘completely stratified’ and the ‘MetaCor’ analyses are slightly
more flexible than the stratified variance model because they
allow for different genetic variance components across analysis
groups, in addition to different residual variance components.
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For BMI, we removed eight individuals from the “completely
stratified” analysis to ensure individuals were unrelated across
groups, defined as less than third-degree relatedness. All analyses,
other than MetaCor, used the GENESIS R package.
Computing variant-specific inflation factors in mixed models
with residual rank-normalization. We studied the calibration of
the various analyses of HGB and BMI by computing approximate
variant-specific inflation factors λvs and, for diagnostics, gener-
ated QQ-plots as describe later. Notably, λvs were developed
assuming independent data, and applying them in the mixed
model settings provides only an approximation, as both the
sample size is inaccurate (e.g., two full siblings have similar
genetic data, so their effective sample size is <2), and there is
more than a single variance parameter, and thus it is not straight
forward to decide which variance estimates to use in computing
λvs. To see that, consider the mixed- model analysis. We modeled
both an error and a genetic variance component, so that for each
observation, the model, in matrix form, assumes that:
y ¼ Xβþ gjαj þ ϵ; with covðϵÞ ¼ σ2e I þ σ2gG
Where G is the GRM, and σ2e ; σ
2
g are error and genetic variance




In addition, we applied the fully-adjusted two-stage procedure
for rank-normalization of residuals, another procedure unac-
counted for by the algorithm. Therefore, different possible models
will yield quite different variance estimates to be used in the λvs
computations, due to changes to the residual distributions due to
rank-normalization. Because we are alerting the readers to the
problems arising from assuming that variances are the same
across all studies, we used variance computed based on the
‘homogeneous variance’ null model (the same residual and
genetic variance components for all analysis groups). We
extracted marginal residuals (distinguished from conditional
residuals that can also be computed in mixed models) for each
group, and computed empirical variance for group j by
vj ¼ 1=nj ∑
i2Sj
bϵ2i . Note that this estimator does not account for
relatedness. We used the residuals from the second null model
from the two-stage procedure.
Assessing population stratification at the variance level
through QQ-plots. Once λvs are computed for each of the var-
iants of interest, we propose to generate QQ-plots across sets of
variants to visualize whether population stratification at the
variance level is appropriately addressed. A function is available
on the GitHub repository to generate QQ-plots stratifying var-
iants to categories: “Inflated”, “Deflated” and “Approx. no infla-
tion”. The categories can be manually defined, so that a variant
can be assigned to the “Inflated” category if its λvs is larger than a
user-specified value, e.g., 1.01. Similarly, a variant is assigned to
the “Deflated” category if its λvs is lower than a user-specified, e.g.,
0.99. Variants are assigned to the “Approx. no inflation” category
if they are not in the “Inflated” or “Deflated” categories, i.e., their
λvs is close to the desired value of 1.
Characterizing variants by inflation patterns. To study how
common the variant inflation/deflation problem is, and how it
relates to variant frequencies, we computed the proportion of
variants in levels of λvs for each allele frequency category: <0.01,
0.01–0.05, 0.05–0.2, and 0.2–0.5. We also studied the similarity of
inflation/deflation patterns between BMI and HGB.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
TOPMed (https://www.nhlbiwgs.org/) whole genome sequencing data are available, from
TOPMed Freeze 5b and Freeze 8, on dbGaP by application to each of the studies used in
this manuscript. Phenotypes can also be obtained through application to dbGaP. Study
dbGaP accessions are: phs000956 (Amish; ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?id=phs000956); phs000954 (CFS; https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?id=phs000954); phs000951 (COPDGene; https://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?id=phs000951); phs000988 (CRA; https://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000988.v4.p1); phs000974 (FHS;
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974.v1.
p1); phs000964 (JHS; https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000964.v4.p1). Source data are provided with this paper. Because Figs. 2
and 3 are based on results from testing tens of millions of variants, source data are
provided after randomly sampling a smaller subset of data points out of those with p
value > 0.01. Source data are provided with this paper.
Table 3 Analysis groups/strata participating in the analysis of hemoglobin concentration.
Study Race/ethnic group N Male sex number (%) Age mean (SD) Hemoglobin mean (SD)
Amish European American 1102 557 (50.5%) 50.6 (16.9) 13.8 (1.2)
FHS European American 3133 1512 (48.3%) 58.5 (15.0) 14.1 (1.3)
JHS African American 3251 1212 (37.3%) 54.8 (12.8) 13.0 (1.5)
For each group, we report parent study, race/ethnic group, number of participants, number and percentage of males, and age and hemoglobin’s means and standard deviations.
Table 2 Analysis groups/strata participating in the BMI analysis.
Study Race/ethnic group N Male sex number (%) Age Mean (SD) BMI mean (SD)
Amish European American 1106 556 (50.3%) 51.9 (16.9) 27.1 (4.7)
CFS African American 472 205 (43.4%) 40.0 (19) 32.7 (9.6)
CFS European American 471 235 (49.9%) 44.0 (19.6) 31.0 (9)
COPDGene African American 881 519 (58.9%) 58.7 (6.7) 28.4 (6.7)
COPDGene European American 995 505 (50.8%) 63.8 (8) 27.9 (5.7)
CRA Costa Rican 550 285 (51.8%) 18.9 (16.1) 20.8 (5.3)
FHS European American 3576 1584 (44.3%) 37.2 (9) 25.6 (4.8)
JHS African American 1756 641 (36.5%) 40.3 (9.9) 25.8 (4.7)
For each group, we report parent study, race/ethnic group, number of participants, number and percentage of males, and age and BMI’s means and standard deviations.
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Code availability
Statistical analyses were performed using the freely available R software, version 4.0.0.
Association testing used the GENESIS package version 2.18.0, available on R/
Bioconductor, or using the MetaCor R package available on GitHub https://github.com/
tamartsi/MetaCor. Code for computing variant-specific inflation factors is available on
GitHub https://github.com/tamartsi/Variant_specific_inflation with a tutorial, code, and
example simulated data provided also in Supplementary Software 1. The code will also
become available as part of GENESIS in a future release. Figures were generated using the
ggplot2 R package version 3.3.0.
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